

		EMLc	ATC codes: L01CB01
Indication	Osteosarcoma of bone and articular cartilage of unspecified sites		
INN	Etoposide		
Medicine type	Chemical agent		
List type	Complementary (EML) (EMLc)		
Formulations	Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule ; 100 mg in vial powder for injection (as phosphate) Oral > Solid: 100 mg capsule ; 50 mg capsule		
EML status history	First added in 2021 (TRS 1035) Changed in 2023 (TRS 1049)		
Sex	All		
Age	Also recommended for children		
Therapeutic alternatives	The recommendation is for this specific medicine		
Patent information	Patents have expired in most jurisdictions Read more about patents . 		
Tags	Cancer		
Wikipedia	Etoposide 		
DrugBank	Etoposide 		

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the inclusion of an additional dose form of etoposide (Powder for injection: 100 mg (as phosphate) in vial) to the EML and EMLc.

